- Home
- RGC vs IMNM Comparison
RGC vs IMNM Comparison
Compare RGC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | IMNM |
|---|---|---|
| Founded | 2014 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | RGC | IMNM |
|---|---|---|
| Price | $6.13 | $21.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 159.8K | ★ 1.0M |
| Earning Date | 10-31-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.51 | $11.25 |
| 52 Week High | $69.00 | $30.06 |
Technical Indicators
Market Signals| Indicator | RGC | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 32.23 |
| Support Level | $5.48 | $19.39 |
| Resistance Level | $6.28 | $23.25 |
| Average True Range (ATR) | 0.33 | 1.16 |
| MACD | 0.05 | -0.44 |
| Stochastic Oscillator | 70.65 | 10.79 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About IMNM Immunome Inc.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.